Ovarian Cancer Subtypes May Predict Response to Bevacizumab
1,341 views · Published 23 June 2014 · 1:59 · Indexed 18 October 2026
Channel: Mayo Clinic · 2014 · Science & Technology
Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. For more information
More from this channel
-
2:19
Nose Job for Snoring-Mayo Clinic
-
1:54
Jazz Doctor-Mayo Clinic
-
2:07
Healthy Heart Numbers - Mayo Clinic
-
2:09
Managing Your Medications-Mayo Clinic
-
1:54
Exercise Safety - Mayo Clinic
-
2:16
Kids Eating Healthy-Mayo Clinic
-
2:09
Sports Rehabilitation and Performance-Mayo Clinic
-
2:17
Transplant Advances-Mayo Clinic